Daniel Hertz, PharmD, PhD
College of Pharmacy
428 Church St
Ann Arbor, MI 48109-1065
Summary
Daniel L Hertz received a PharmD from the Ernest Mario School of Pharmacy at Rutgers University in 2008 and a PhD in Pharmaceutical Sciences from the UNC Eshelman School of Pharmacy in 2013. He has always had a passion for cancer research. During his PhD, Dr. Hertz worked with Dr. Howard McLeod, who introduced him to the field of cancer pharmacogenetics. Dr. Hertz’s dissertation research focused on discovery and validation of pharmacogenetic predictors of taxane-induced neuropathy. After receiving his PhD, Dr. Hertz joined the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy where he is currently an Associate Professor.
Dr. Hertz’s current research is interested in developing tools for individualizing treatment in patients with cancer and translating them into clinical practice. His NCI R37 uses data and biospecimens collected on the prospective SWOG S1714 clinical trial to discover biomarkers (e.g., kinetics, genetics, metabolomics, nutrients) of taxane-induced peripheral neuropathy that can be used to identify patients at higher risk of neuropathy, in whom personalized treatment approaches or experimental preventive strategies can be investigated. He is also an advocate and researcher in the area of DPYD testing to prevent severe fluoropyrimidine toxicity. He is a Medical Advisor to the Advocates for Universal DPD/DPYD Testing and has published several manuscripts describing the clinical utility of pre-treatment DPYD testing.
Accepting PhD Students.
Research Interests
Developing tools for individualizing cancer treatments
Understanding the role of patient genetics in treatment outcomes
Translating genetic associations into clinical practice to improve patient care
Awards
- 2013 Graduate Education Advancement Board Impact Award, UNC GEAB
Selected Publications
Hertz DL, McShane LM, Hayes DF, Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective. J Clin Oncol. 2022;24(10):02209. doi: 10.1200/JCO.21.02209. [Epub ahead of print] PubMed PMID: 35324346.
Chen CS, Kim J, Garg N, Guntupalli H, Jagsi R, Griggs JJ, Sabel M, Dorsch MP, Callaghan B, Hertz DL. Chemotherapy-induced peripheral neuropathy detection via smartphone app: a cross-sectional pilot study. JMIR Mhealth Uhealth 2021;9(7):e27502 doi: 10.2196/27502
Hertz DL, Kidwell KM, Vangipuram K*, Li F, Pai MP, Burness ML, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Smith EM, Henry NL. Paclitaxel Plasma Concentration After the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clin Cancer Res. 2018 Apr 27. pii: clincanres.0656.2018. doi: 10.1158/1078-0432.CCR-18-0656. [Epub ahead of print] PubMed PMID: 29703818.
Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech L, Loprinzi CL, Ruddy KJ, Lustberg M. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat Rev. 2021 Jun 9;99:102241. doi: 10.1016/j.ctrv.2021.102241. [Epub ahead of print] Review. PubMed PMID: 34174668.
Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens ST, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.
Mc Laughlin AM, Helland T^, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL, On behalf of the CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Clin Pharmacol Ther. 2024 Mar 18;. doi: 10.1002/cpt.3238. [Epub ahead of print] PubMed PMID: 38494911.
Chen CS, Zirpoli G, Barlow WE, Budd GT, McKiver B, Pusztai L, Hortobagyi GN, Albain KS, Damaj MI, Godwin AK, Thompson A, Henry NL, Ambrosone CB, Stringer KA, Hertz DL. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. J Natl Compr Canc Netw. 2023 Nov;21(11):1172-1180.e3. doi: 10.6004/jnccn.2023.7062. PubMed PMID: 37935109; PubMed Central PMCID: PMC10976748.
Baker S, Brooks G, Dahut B, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper T, McLeod HL, O’Donnell P, Relling MV, Rudek M, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko C. DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23. PubMed PMID: 36821823; PubMed Central PMCID: PMC10414691.
Hertz DL. Assessment of the Clinical Utility of Pretreatment DPYD Testing for Patients Receiving Fluoropyrimidine Chemotherapy. J Clin Oncol. 2022 Nov 20;40(33):3882-3892. doi: 10.1200/JCO.22.00037. Epub 2022 Sep 15. PubMed PMID: 36108264.
